CanSino Biologics (DB:CJH) - Hisse Senedi Fiyatı, Haberler ve Analizler

CJH Stoklara Genel Bakış

CanSino Biologics Inc. Çin Halk Cumhuriyeti'nde aşı geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay

CJH temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 90.3% daha düşük bir oranda işlem görüyor

Kazançların yılda 141.45% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

CanSino Biologics Inc. Rakipler

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€844.9m

Heidelberg Pharma

XTRA:HPHA

€106.7m

Medigene

XTRA:MDG1

€20.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti CanSino Biologics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$3.20
52 Haftanın En Yüksek Seviyesi	HK$4.22
52 Haftanın En Düşük Seviyesi	HK$1.81
Beta	0.49
11 Aylık Değişim	5.26%
3 Aylık Değişim	68.42%
1 Yıllık Değişim	2.56%
33 Yıllık Değişim	-83.16%
5 Yıllık Değişim	-47.11%
Halka arzdan bu yana değişim	-8.05%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	CJH	DE Biotechs	DE Pazar
7D	-6.4%	0.8%	0.8%
1Y	2.6%	-18.3%	8.6%

Getiri vs. Endüstri: CJH geçen yıl % -18.3 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: CJH geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CJH's price volatile compared to industry and market?
CJH volatility
CJH Average Weekly Movement	14.3%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: CJH hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CJH 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	1,149	Xuefeng Yu	www.cansinotech.com

CanSino Biologics Inc. Çin Halk Cumhuriyeti'nde aşı geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, rekombinant yeni koronavirüs hastalığına karşı Convidecia ve İnhalasyon aşıları için Ad5-nCoV; bir Ebola virüsü aşısı olan Ad5-EBOV; ve N. meningitides'in önlenmesi için MCV2 ve MCV4 aşılarını geliştirmektedir. Bebekler için DTcP aşısı ve birincil aşılamadan sonra boğmacayı önleyen zayıf korumayı ele almak için Faz I klinik çalışmasında olan DTcP Booster aşısını geliştirmektedir.

CanSino Biologics Inc. Temel Bilgiler Özeti

CanSino Biologics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CJH temel i̇stati̇sti̇kler
Piyasa değeri	€1.40b
Kazançlar(TTM)	-€95.03m
Gelir(TTM)	€98.78m

8.3x

P/S Oranı

-8.6x

F/K Oranı

CJH aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CJH gelir tablosu (TTM)
Gelir	CN¥748.53m
Gelir Maliyeti	CN¥774.40m
Brüt Kâr	-CN¥25.87m
Diğer Giderler	CN¥694.25m
Kazançlar	-CN¥720.11m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.91
Brüt Marj	-3.46%
Net Kâr Marjı	-96.20%
Borç/Özkaynak Oranı	41.3%

CJH uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CJH Stoklara Genel Bakış

Ödüller

Risk Analizi

CanSino Biologics Inc. Rakipler

XTRA:BIO3

€1.4b

XTRA:FYB

€844.9m

XTRA:HPHA

€106.7m

XTRA:MDG1

€20.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.58 loss in 3Q 2023)

New minor risk - Profitability

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

High number of new directors

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Recent updates

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.58 loss in 3Q 2023)

New minor risk - Profitability

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

High number of new directors

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

First quarter 2024 earnings released: CN¥0.69 loss per share (vs CN¥0.57 loss in 1Q 2023)

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

Full year 2023 earnings released: CN¥6.01 loss per share (vs CN¥3.68 loss in FY 2022)

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings released: CN¥5.87 loss per share (vs CN¥3.68 loss in FY 2022)

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Less than half of directors are independent

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

Less than half of directors are independent

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Less than half of directors are independent

Full year 2022 earnings released: CN¥3.68 loss per share (vs CN¥7.74 profit in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Less than half of directors are independent

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold €414k worth of stock

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Now 31% undervalued

Third quarter 2022 earnings released

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.06 loss in 1Q 2021)

Less than half of directors are independent